Drug Trial Radar · NCT01779206
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,936
Planned (sponsor's estimate)
Start
May 2012
Primary completion
Sep 2019
Study completion Jan 15, 2025
Sponsor
- Lead sponsor
- Women's Cancer Study Group GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
Conditions
- Breast Cancer
Interventions
EpirubicinDrug
CyclophosphamideDrug
DocetaxelDrug
PaclitaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS≤11Time frame: 3 Years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern
Munich, Bavaria, Germany
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein
Mönchengladbach, North Rhine-Westphalia, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.